Cinclus Pharma (CINPHA) Q1 2026 earnings summary

Executive summary

• Linaprazan glurate, a next-generation PCAB, targets severe erosive GERD with sustained 24-hour acid control and clinical differentiation from PPIs and first-generation PCABs, aiming for best-in-class status.

• Phase III HEEALING 1 study is nearing full enrollment, with topline results expected in Q4 2026, representing a major value catalyst.

• Commercial launch in China achieved in Q1 2026 via Sinorda license and local partner Huadong, with national reimbursement secured; Zentiva license for Europe valued at EUR 220 million.

• Regulatory alignment and positive feedback achieved with both FDA and EMA, with FDA allowing a single pivotal study for US approval and no additional toxicology studies required.

• EUR 28 million financing agreement secured with Claret Capital Partners, supporting late-stage clinical development and pre-launch activities.

Financial highlights

• Q1 2026 net sales reached SEK 10 million (TSEK 10,036), up from zero last year, driven by licensing revenue from Zentiva (Europe) and Sinorda (China).

• Operating expenses rose to SEK 100 million, mainly due to increased R&D for the phase III program.

• Net loss for Q1 2026 was SEK 88.8 million (TSEK -88,768), compared to SEK 33.7 million in Q1 2025, mainly due to higher R&D expenses.

• Cash and cash equivalents at period end were SEK 475.8 million (TSEK 475,849), down from SEK 487 million at end of 2025.

• Cash flow for Q1 2026 was minus SEK 12.7 million (TSEK -12,712), an improvement from minus SEK 42 million in Q1 2025.

Outlook and guidance

• Current cash position is expected to fund operations into Q3 2027 under current assumptions, covering completion of the first Phase III program.

• Cost base will remain high in coming quarters due to phase III activities, with a decrease expected after trial completion.

• Preparations for HEEALING 2 phase III trial are underway, aiming for initiation in 2027, contingent on HEEALING 1 results.

• Topline Phase III results expected in Q4 2026, with subsequent studies planned including US sites.

• Financing agreement enables accelerated development and earlier start of final Phase III stages.